Crump Institute for Molecular Imaging; Institute for Molecular Medicine; Jonsson Comprehensive Cancer Center, California NanoSystems Institute, David Geffen School of Medicine, Department of Molecular & Medical Pharmacology, University of California, Los Angeles CA 90095, USA.
David Geffen School of Medicine, Division of Rheumatology, University of California, Los Angeles CA 90095, USA.
Sci Signal. 2011 Mar 29;4(166):ra18. doi: 10.1126/scisignal.2001314.
In subtypes and late stages of leukemias driven by the tyrosine kinase fusion protein Bcr-Abl, signaling by the Src family kinases (SFKs) critically contributes to the leukemic phenotype. We performed global tyrosine phosphoprofiling by quantitative mass spectrometry of Bcr-Abl-transformed cells in which the activities of the SFKs were perturbed to build a detailed context-dependent network of cancer signaling. Perturbation of the SFKs Lyn and Hck with genetics or inhibitors revealed Bcr-Abl downstream phosphorylation events either mediated by or independent of SFKs. We identified multiple negative feedback mechanisms within the network of signaling events affected by Bcr-Abl and SFKs and found that Bcr-Abl attenuated these inhibitory mechanisms. The C-terminal Src kinase (Csk)-binding protein Pag1 (also known as Cbp) and the tyrosine phosphatase Ptpn18 both mediated negative feedback to SFKs. We observed Bcr-Abl-mediated phosphorylation of the phosphatase Shp2 (Ptpn11), and this may contribute to the suppression of these negative feedback mechanisms to promote Bcr-Abl-activated SFK signaling. Csk and a kinase-deficient Csk mutant both produced similar globally repressive signaling consequences, suggesting a critical role for the adaptor protein function of Csk in its inhibition of Bcr-Abl and SFK signaling. The identified Bcr-Abl-activated SFK regulatory mechanisms are candidates for dysregulation during leukemia progression and acquisition of SFK-mediated drug resistance.
在由酪氨酸激酶融合蛋白 Bcr-Abl 驱动的白血病亚型和晚期阶段,Src 家族激酶 (SFKs) 的信号传导对白血病表型至关重要。我们通过定量质谱法对 Bcr-Abl 转化细胞进行了全局酪氨酸磷酸化谱分析,这些细胞的 SFK 活性受到干扰,以构建一个详细的、依赖于上下文的癌症信号网络。通过遗传学或抑制剂干扰 SFKs Lyn 和 Hck,揭示了 Bcr-Abl 下游磷酸化事件要么由 SFKs 介导,要么独立于 SFKs。我们在受 Bcr-Abl 和 SFKs 影响的信号事件网络中鉴定了多个负反馈机制,并发现 Bcr-Abl 减弱了这些抑制机制。C 末端Src 激酶 (Csk)-结合蛋白 Pag1(也称为 Cbp)和酪氨酸磷酸酶 Ptpn18 都介导对 SFKs 的负反馈。我们观察到 Bcr-Abl 介导的磷酸酶 Shp2(Ptpn11)的磷酸化,这可能有助于抑制这些负反馈机制,以促进 Bcr-Abl 激活的 SFK 信号传导。Csk 和一个激酶缺陷的 Csk 突变体都产生了类似的全局抑制性信号后果,这表明 Csk 的衔接蛋白功能在其抑制 Bcr-Abl 和 SFK 信号传导中起着关键作用。鉴定的 Bcr-Abl 激活的 SFK 调节机制是白血病进展过程中失调和获得 SFK 介导的耐药性的候选机制。